<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04145492</url>
  </required_header>
  <id_info>
    <org_study_id>12</org_study_id>
    <nct_id>NCT04145492</nct_id>
  </id_info>
  <brief_title>Effect of Vitamin K 2 on Vascular Calcification in Hemodialysis Patients</brief_title>
  <official_title>The Impact of Vitamin K2 and Inactive Vitamin D Supplementation on Vascular Calcification in Pediatric Patients on Regular Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the effect of supplementation of vitamin K2 (menaquinone,
      MK-7) and cholecalciferol (inactive vitamin D) on circulating levels of calcification
      regulators and to assess their safety in pediatric patients on regular hemodialysis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vascular calcification occurs in more than half of chronic renal failure patients, which
      mainly appears in the large and medium size arteries [3, 4]. It seems that vas¬cular
      calcification is caused by dynamic imbal-ance of intravascular calcium and phosphorus.
      However, more and more studies pointed out that vascular calcification were related with
      local cell's function and biological characteris¬tics.

      The aim of this study is to assess the effect of supplementation of vitamin K2 (menaquinone,
      MK-7) and cholecalciferol (inactive vitamin D) on circulating levels of calcification
      regulators and to assess their safety in pediatric patients on regular hemodialysis patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Uncarboxylated MGP</measure>
    <time_frame>4 months</time_frame>
    <description>Measuring serum level of Uncarboxylated MGP as a marker for calcification</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Uncarboxylated osteocalcin</measure>
    <time_frame>4 months</time_frame>
    <description>Measuring serum level of Uncarboxylated osteocalcin as a marker for calcification</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Vitamin K2 group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 patients will take 90 ug of vitamin K2 (MK-7) daily in addition to the standard therapy for 4 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cholecalciferol group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 patients will take 10 ug of vitamin inactive vitamin D daily in addition to the standard therapy for 4 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin K2 and Cholecalciferol group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 patients will take 90 ug of vitamin K2 (MK-7) in addition 10 ug of vitamin inactive vitamin D to daily in addition to the standard therapy for 4 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>15 patients will take the standard therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin K2</intervention_name>
    <description>Patients will take 90 ug of vitamin K2</description>
    <arm_group_label>Vitamin K2 group</arm_group_label>
    <other_name>Group 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol (inactive vitamin D)</intervention_name>
    <description>Patients will take 10 ug of vitamin inactive vitamin D</description>
    <arm_group_label>Cholecalciferol group</arm_group_label>
    <arm_group_label>Vitamin K2 and Cholecalciferol group</arm_group_label>
    <other_name>Group 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin K2 and Cholecalciferol</intervention_name>
    <description>Patients will take 90 ug of vitamin K2 (MK-7) in addition 10 ug of vitamin inactive vitamin D</description>
    <arm_group_label>Vitamin K2 and Cholecalciferol group</arm_group_label>
    <other_name>Group 3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients aged 6-18 years

          -  Patients on hemodialysis since 3 months or longer

          -  Hemodialysis frequency 3 times or more weekly

        Exclusion criteria:

          -  Patients with life expectancy &lt; 3 months

          -  Patients taking warfarin

          -  Patients with known intestinal malabsorption
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Radwa Maher El Borolossy</name>
      <address>
        <city>Cairo</city>
        <zip>0000</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radwa Maher El Borolossy, PhD</last_name>
      <phone>01227052880</phone>
      <email>radwa.maher14@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 28, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2019</study_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Radwa Maher Abd El Kader El Borolossy</investigator_full_name>
    <investigator_title>lecturer of clinical pharmacy</investigator_title>
  </responsible_party>
  <keyword>Hemodialysis and Vitamin K2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Vascular Calcification</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Vitamin K 2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

